Sponsor
Neal Patrick Dunn
Representative · R-FL
Representative · R-FL
Official title: To amend the Public Health Services Act, commonly referred to as the "Clinical Laboratory Improvement Amendments" or "CLIA", with respect to laboratory developed tests, and for other purposes.
Introduced May 19, 2026 by Neal Patrick Dunn · Last progress May 19, 2026
The bill modernizes and centralizes oversight of laboratory‑developed tests to improve safety, transparency, and access to advanced diagnostics, but it imposes significant compliance costs, legal complexity, risks to smaller labs and trade‑secrets/privacy, and transition‑period disruptions that could raise prices and complicate emergency responses.
Patients and clinicians will face clearer, LDT‑specific federal standards, registration, and quality‑system requirements and gain authorization to regulate modern test types (e.g., molecular diagnostics, NGS), improving test reliability and access to up‑to‑date diagnostics.
Clinical laboratories and test developers get a 2‑year implementation window and clear regulatory deadlines (proposed regs in 180 days, final regs in 2 years), giving industry time and regulatory certainty to adapt without immediate service disruption.
Mandatory adverse‑event and test‑error reporting lets regulators, clinicians, and labs more quickly detect and address harmful or malfunctioning tests, improving patient safety.
Clinical laboratories (especially hospital and independent labs) will face substantial new compliance costs and administrative burdens for registration, premarket submissions, quality systems, reporting, and maintaining database entries.
Smaller or independent labs are likely to struggle more with meeting standards and paying required fees (including potential FDA parity fees), creating a competitive disadvantage and risking local lab closures or consolidation.
HHS/FDA authority to suspend LDTs after findings could lead to rapid test pauses or removals that disrupt patient care while labs remediate issues.
Based on analysis of 4 sections of legislative text.
Establishes a standalone federal regulatory regime for LDTs requiring registration, many premarket submissions, quality systems, reporting, and updated CLIA processes.
Creates a new, standalone federal regulatory framework for laboratory-developed tests (LDTs) under the Public Health Service Act and strengthens CLIA rulemaking and stakeholder engagement. The bill requires many LDTs to register and submit premarket information, meet quality system and adverse event reporting standards, and comply with phased deadlines and new definitions, while directing HHS and CMS to update CLIA exam types, transparency, and public comment processes. Most statutory changes are effective on enactment; agencies must propose rules within 180 days and finalize several items within two years, though broader regulatory implementation is phased.